文献速递肺血管病与心包/心肌炎

肺动脉高压的变革:关键里程碑与未来展望

Transforming Pulmonary Arterial Hypertension: Key Milestones and Future Perspectives.
PubMed 文献 · Circulation · 2026-07-13

本文综述肺动脉高压(PAH)四十年来的病理生物学、流行病学、诊断与治疗进展。PAH涉及内皮功能障碍、平滑肌增殖、炎症及前列腺环素、一氧化氮、内皮素1、BMP/TGF-β通路失调;sotatercept为首个获批的抗重构治疗。诊断仍延迟,右心导管为确诊必需,多数患者起始联合口服治疗,高危者初始含肠外前列环素的三联治疗。

要点

  • PAH为罕见进展性毛细血管前肺小动脉病,以纤维增殖性血管重构、肺血管阻力升高、右心衰竭和早亡为特征。
  • TGF-β通路activin臂失调是血管重构的关键驱动因素,sotatercept为其靶向的首个抗重构治疗。
  • 多数患者起始联合两种口服药物,高危者初始含肠外前列环素的三联治疗,未达低危者可加用sotatercept。

核心结论

  • 过去四十年PAH在病理生物学、流行病学、诊断和治疗方面取得实质性进展,患者结局显著改善。
  • 尽管治疗进展显著,早期检出、合并症表型管理、个体化治疗及靶向右心衰竭的新疗法仍存在差距。

研究设计与样本

  • 本文为综述,总结PAH病理生物学、流行病学、诊断与治疗的关键里程碑及未来方向。

主要发现

  • PAH病理生物学涉及内皮功能障碍、平滑肌细胞过度增殖、炎症及前列腺环素、一氧化氮、内皮素1、BMP/TGF-β轴失调。
  • TGF-β通路activin臂失调是血管重构的关键驱动因素,为sotatercept的靶点。
  • PAH现更多影响伴有心血管和肺部合并症的老年人;北美甲基苯丙胺相关PAH上升,低中收入国家血吸虫和HIV相关PAH常见。
  • 诊断持续延迟,多数患者确诊时已有晚期症状,右心导管仍是确诊必需。
  • 人工智能应用于心电图、超声心动图和电子健康记录有望早期识别病例。

关键数值与推荐

  • PAH管理及预后基于经验证的多参数工具进行定期风险分层。
  • 多数患者起始联合两种口服药物,高危患者初始含肠外前列环素的三联治疗。
  • 未达低危者加用sotatercept为可选策略。

临床怎么用

  • 对PAH患者应定期使用经验证的多参数工具进行风险分层,并据此选择起始联合或加用治疗。
  • 右心导管用于确诊;对最大治疗后仍高危者应考虑肺移植评估。

局限性

  • 早期检出、合并症表型管理、个体化治疗及靶向右心衰竭的新疗法仍存在差距。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Pulmonary arterial hypertension (PAH) is a rare, progressive disease of the precapillary pulmonary arteries, characterized by fibroproliferative vascular remodeling, increased pulmonary vascular resistance, right ventricular failure, and premature death. Over the past four decades, substantial advances in understanding PAH pathobiology, epidemiology, diagnosis, and treatment have meaningfully improved patient outcomes. The pathobiology of PAH is multifaceted, involving endothelial dysfunction, smooth muscle cell hyperproliferation, inflammation, and dysregulation of key signaling pathways, including the prostacyclin, nitric oxide, endothelin 1, and bone morphogenetic/TGF-β (transforming growth factor β) axes. Dysregulation of the activin arm of the TGF-β pathway has emerged as a critical driver of vascular remodeling and is the target of sotatercept, the first antiremodeling therapy approved for PAH. Epidemiologically, PAH now more commonly affects older adults with cardiovascular and pulmonary comorbidities compared with historical cohorts. The global burden varies considerably, with methamphetamine-associated PAH rising in North America and schistosomiasis- and HIV-associated PAH prevalent in low- and middle-income countries, where underdiagnosis likely remains substantial. Diagnosis continues to be delayed, with advanced symptoms present at the time of diagnosis for most patients. Right heart catheterization remains essential for definitive diagnosis. Emerging tools, including artificial intelligence applied to electrocardiography, echocardiography, and electronic health records, hold promise for earlier case identification. Management and prognostication of PAH is based on regular risk stratification using validated multiparameter tools. The initial therapy choice is up-front combination therapy with 2 oral medications for most patients, with initial triple therapy that includes a parenteral prostacyclin used in high-risk patients. Add-on therapy with sotatercept is now an option for patients not achieving low risk, a strategy that led to improvements in hemodynamics, right heart function, and reduced the risk of adverse clinical outcomes in recent randomized trials. For patients who remain at higher risk despite maximal therapy, lung transplantation remains an important and life-saving option. Despite remarkable therapy progress, gaps persist in earlier detection, management of comorbid phenotypes, personalized therapy, and novel therapies targeting right ventricular failure. Ongoing clinical trials and translational research continue to advance the field toward the goal of normal survival and quality of life for patients with PAH.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Humbert M, Zeder K, Kovacs G, et al. Transforming Pulmonary Arterial Hypertension: Key Milestones and Future Perspectives. Circulation. 2026. PMID: 42441757. doi:10.1161/CIRCULATIONAHA.126.079274

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。